What’s the current market cap for DaVita stock?

DaVita (DVA) has a market cap of $13bn as of June 17, 2026.

What is the P/E ratio for DaVita stock?

The price to earnings (P/E) ratio for DaVita (DVA) stock is 19.46 as of June 17, 2026.

Does DaVita stock pay dividends?

No, DaVita (DVA) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next DaVita dividend payment date?

DaVita (DVA) stock does not pay dividends to its shareholders.

What is the beta indicator for DaVita?

DaVita (DVA) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy DaVita stock | $DVA Share Price

13:30

15:10

16:45

18:25

20:00

About DaVita

DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Ticker

$DVA

Sector

Health

Primary listing

NYSE

Employees

78,000

Headquarters

Denver, United States

Website

www.davita.com

DaVita Metrics

BasicAdvanced

$13bn

19.46

$10.74

0.91

What the Analysts think about DaVita

Analyst ratings (Buy, Hold, Sell) for DaVita stock.

Bulls say / Bears say

DaVita’s Q1 revenue was $3.42 billion, up 6% year-over-year, and adjusted EPS reached $2.87, both surpassing analysts’ forecasts of $3.36 billion in revenue and $2.32 EPS, which shows strong performance on both revenue and earnings.

Management increased its 2026 adjusted EPS guidance to $14.10–$15.20 from $13.60–$15.00, reflecting confidence in ongoing demand and effective cost control.

The stock jumped more than 3% in after-hours trading on May 5 after the company’s better-than-expected results and higher guidance, signaling strong investor confidence.

CMS’s CY 2026 ESRD PPS final rule raised the base dialysis payment rate by just 2.2%, which may not keep up with rising cost inflation for dialysis providers and could pressure margins.

DaVita has faced higher patient care and operating costs in recent quarters, and these pressures may return, affecting profitability.

Commercial payers represent about a third of DaVita’s revenue but provide nearly all its profits, leaving the company exposed to potential negative changes in commercial reimbursement rates.

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

DaVita Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

DaVita Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DVA

Capital at risk

Market closed

Upcoming events

No upcoming events